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The yeast S. cerevisiae has been examined as a heterologous host for the expression of mammalian eurotransmitter r ceptors which couple to 
guanine nucleotide regulatory (G) proteins. A cloned gene encoding the MI subtype of human muscarinic receptor (HM1) was transformed into 
S. cerevisiae on a high copy plasmid under the control of the promoter for the yeast alcohol dehydrogenase (ADH) gene. Northern blotting demon- 
strated the presence of HM 1 transcripts in transformants, and crude membranes prepared from these cells showed saturable binding of the musea- 
rinic antagonist pH] N-methyl scopolamine with a Kd of 179 pM and Bm~ of 20 fmol/mg protein. Competition binding studies revealed pharmacolo- 
gical properties for these sites which were comparable to those reported for the M1 site in mammalian tissues. Yeast expressing HM1 did not 
exhibit high atfinity agonist binding or cell-cycle arrest in the presence of muscarinic agonists, indicating that the mammalian receptor did not 
couple to the endogenous yeast G protein. 
Gene expression; Radioligand binding; Acetylcholine r ceptor; Yeast; G protein 
1. INTRODUCTION 
The plasma membrane r ceptors for a wide variety of 
neurotransmitters and biologically-active peptides 
function through interactions with intracellular guanine 
nucleotide r gulatory (G) proteins (reviewed in [ 1]). The 
application of molecular genetic techniques has provid- 
ed cloned DNA and protein sequences for many recep- 
tors of this class; all are single polypeptides which are 
predicted to fold, like bacteriorhodopsin, i to 7 mem- 
brane-spanning a-helices [1]. Heterologous expression 
of the cloned genes encoding these receptors in mam- 
malian or amphibian host cells provides apowerful tool 
to investigate signalling mechanisms and receptor 
structure-function (reviewed in [2]). Such systems are 
also expected to generate the quantities of these rare 
proteins necessary for structure determination, and to 
provide novel reagents to the pharmaceutical industry 
for drug-screening applications [3]. 
The ability to use microorganisms as hosts for the ex- 
pression of mammalian receptors with 'native' proper- 
ties would provide easily manipulated, low-cost alter= 
natives to current systems for use in large-scale drug 
screening programs, analysis of receptor mutants and 
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high level production. The eukaryote S. cerevisiae is a 
particularly attractive candidate for such applications, 
since it possesses ignal transducing machinery with 
remarkable similarities to mammalian G protein 
coupled systems. Specifically, the receptors for the pep- 
tide mating pheromones a- and a-factors, termed STE2 
and STE3, respectively, share the putative 7-helix struc- 
tural motif and couple to a trimeric G protein with se- 
quence similarities to mammalian G proteins [4,5]. In 
the present study, we have examined S. cerevisiae as a 
heterologous host for the expression of mammalian G 
protein-coupled receptors using a cloned gene encoding 
the M1 subtype of human muscarinic receptor (HM1) 
[6]. 
2. MATERIAL AND METHODS 
2.1. Chemicals 
[3H]NMS was purchased from Amersham, atropine, oxotremorine 
and carbachol were from Sigma and 4-DAMP, pirenzepine, methoc- 
tramine and ( + )QNB were from Research Biochemical Inc. Zymolase 
100T was purchased from ICN Biomedicals, Klenow enzyme, restric- 
tion enzymes and BamH 1 linkers from Boehringer-Mannheim, PMSF 
from Gibco/BRL and guanidinium thiocyanate from Fluka. 
2.2. Vector construction 
All recombinant DNA procedures were based on standard pro- 
tocols [7]. A ca 4 kb human genomic fragment was provided [6] which 
contained the intronless coding portion of the HM 1 gene plus approx- 
imately 1.7 and 0.9 kb of 5'- and 3'-non-coding sequences, respec- 
tively. Digestion with SauI and SmaI yielded the 1.4 kb coding region 
flanked by short non-coding sequences. This fragment was blunt- 
ended using Klenow DNA polymerase I fragment and subcloned into 
the BamH1 site of the yeast expression vector pVTI02-U [8] using 
synthetic BamHI linkers. The remaining non-coding portions of the 
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HM1 gene were removed by oligonucleotide-directed mutagenesis [9]
using a kit from BioRad (Mutagene). One oligonucleotide (5'- 
TACAATCAACTCCAAGCTGGATCCATGAACACTCCAGCC- 
CCA-3') directed the 'loop-out' removal of the 5'-flanking sequence 
(73 nucleotides), and a second (5'-TCCCGCCAATGCTGA- 
TAGGGATCCAGAGGTTTGGTCAAG-3 ') deleted the 3' -flanking 
sequence (33 nucleotides). The final sequences at the ends of the HM 1 
coding segment, as verified by dideoxy sequencing, are shown in 
Fig. lB. The resulting construct, ermed pVTUHM1 (Fig. 1A), con- 
tains the complete HM1 coding sequence with BamH1 sites im- 
mediately flanking the translational start and stop codons, and places 
the insert under control of the promoter and 3' -non-coding regions of 
the yeast ADH gene. The yeast strain DJ 213-6-3-a (ade2 ° his4-580 a 
lys2 trpl a tyrl ° tryl sup 4-3 's leu2 ura3 STE2::leu2) [10] was 
transformed [11] with either pVTUHM1 or the pVTI02-U vector, and 
colonies elected by growth on solid medium lacking uracil. The HM 1 
coding segment was also inserted into the BamHl site of pGEMI 
(Promega) for the synthesis of HM1 riboprobes. 
2.3. RNA analysis 
Cloned transformants grown overnight at 30°C in yeast minimal 
medium lacking uracil (Y MIN-URA) were converted to spheroplasts 
[1 2] and total RNA prepared [ 1 3]. Following electrophoreses on a 1 07o 
agaraose gel in the presence of formaldehyde and transfer to 
nitrocellulose [7], the Northern blot was hybridized with 32p-labeled 
HM1 anti-sense RNA, washed at high stringency and exposed to X- 
ray film. 
2.4. Membrane preparation 
Yeast grown in Y MIN-URA to approximately I x 107 cells/ml were 
harvested by centrifugation, washed twice in ice-cold lysis buffer 
A ~ ~ %  
( 
B 
~, ADH3' Bsrn HI ~, HN1 B~n H1 ~, ADHp 
5' A~ACCTCTGGAT-CCCTATCA~CA//AGTGTTCATG-G-ATCCAGCTTGGAG 3' 
TTTGGAGACCTAGGGATAGTCGT//TCACAAGTACCTAGGTCGAACCTC 
Fig. 1. (a) Partial map of the expression vector pVTUHM1 con- 
structed as described in the text. The HMI 1.4 kb coding sequence 
(filled arc) is flanked in the vector by the promoter (ADHp) and 
3'-non-coding sequence (ADH3') of the yeast ADH gene (stippled 
arcs). Approximate map position and orientation are also for the E. 
coli of replication (ori), the yeast 2~ origen of replication (2~ ori) and 
the origin of replication and intergenic region of the phage fl (fl ori), 
as well as the B-lactamase (APr) and URA3 genes used as selectable 
markers in E. coil and yeast, respectively. (b) Nucleotide sequence at 
5'- and 3'-ends of the HMI coding segment in the final pVTUHM1 
expression vector. The initiator codon AT(3 is underlined. 
(50 mM Tris, pH 7.4, 1 mM EDTA, 0.1 mM PMSF, 10°70 glycerol) 
and resuspended in the same buffer to yield approximately 5 x 109 
cells/ml. The cells were disrupted by two passages through a French 
press at 20 000 psi, the resulting suspension centrifuged at500 x g for 
5 min and the supernatant centrifuged at100 000xg for 90 min. The 
pellet of crude membranes was resuspended in a minimal amount of 
lysis buffer, homogenized in a glass/teflon homogenizer and stored in 
aliquots at -80°C. The protein concentration of the membrane 
preparations [14] was between 25 to 35 mg/ml. 
2.5. Binding assays 
Membranes were thawed on ice, homogenized again and diluted as 
appropriate in the incubation buffer (50 mM Tris, pH 7.4, 0.1 mM 
PMSF). Assays were conducted in triplicate at a protein concentra- 
tion of 0.5 mg/ml in a final volume of 1 ml. Incubations were per- 
formed for 25°C for 60 rain, at which time equilibrium was achieved 
(not shown). Saturation binding of [3H]NMS was measured at12-15 
concentrations i  the range of 0.003 and 20 nM. For competition ex- 
periments, 12 concentrations of non-radioactive muscarinic agonist 
or antagonist were used with a single concentration of [3H]NMS 
(0.5 riM). Non-specific binding was measured in the presence of lum 
atropine or ( + )QNB, both of which gave the same result. Incubations 
were terminated by vacuum filtration on GF/B filters (Whatman) 
pretreated with 0.3°70 polyethylenimine for3 h to reduce non-specific 
binding of the ligand to the filter. The filters were washed 3times with 
5 ml of ice-cold 50 mM Tris, pH 7.4, placed in vials with 7 ml of liquid 
scintillation cocktail (ACS, Amersham) and radioactivity counted the 
next day at 33070 efficiency. Saturation and competition binding 
parameters were calculated by non-linear multiple regression using a 
computerized curve fitting program (RADLIG, Elsevier-Biosoft). 
3. RESULTS AND DISCUSSION 
Yeast transformants carrying the vector pVT102-U 
alone or the pVTUHM1 construct were examined for 
the presence of HM1 RNA transcripts by Northern 
blotting. As shown in the autoradiogram in Fig. 2, a 
hybridizing band of approximately 1.6 kb was observed 
in the total RNA extract from yeast ransformed with 
the recombinant plasmid but was absent from the con- 
trol. This corresponds in size to that expected for a 
transcript of the HM1 coding region plus the ADH 5'- 
and 3'-non-coding segments. The cloned HM 1 gene is 
thus transcribed in yeast from pVTUHM1. 
Transformants were tested for the presence of 
muscarinic binding sites using the antagonist [3H]NMS 
in saturation experiments. Intact cells did not exhibit 
specific [3HINMS binding over background with either 
plasmid (not shown). Crude membranes prepared from 
cells transformed with pVTUHM1, but not with vector 
filone, showed specific, saturable binding of [3H]NMS 
(Fig. 3a). Data analysis indicated a single class of 
binding sites with a dissociation constant of 
0.179_+0.05 nM (mean _+ SE, n=3) and densities of 
between 1and 20 fmol/mg protein for several different 
preparations (Fig. 3B). This value represents roughly 
2-40 sites/cell. By comparison, the endogenous yeast 
pheromone r ceptor STE2 is normally present in a-cells 
at 3000-8000 copies/cell, this value being raised to as 
high as 100 000/cell in yeast overexpressing the cloned 
STE2 gene from a high-copy plasmid [15]. The dif- 
ference could conceivably reflect inefficient translation 
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Fig. 2. Autoradiogram of a Northern blot of total RNA (2/~g per 
lane) from yeast (DJ-213-6-3-a) transformed with pVT102-U alone 
(control) or the vector harboring the HM1 gene downstream the ADH 
promoter (pVTUHMI). The position of the yeast 18 S and 25 S 
ribosomal RNAs are indicated on the left. 
of HM1 transcripts detected in transformants, or to 
problems in stability, folding and/or processing (e.g. 
glycosylation) ofhuman receptor protein in the heterol- 
ogous yeast host. All of these phenomena h ve been en- 
countered in studies to express mammalian genes in S. 
cerevisiae (reviewed in [16]). The development of 
suitable antisera permitting estimates of the total level 
of HM1 translation products would aid in clarifying 
this point. 
The structural integrity of the muscarinic binding 
sites detected in transformants was assessed by deter- 
mining the affinities of a series of muscarinic ligands in 
competition binding studies with [3H]-NMS. The 
ligands included two agonists (carbachol and ox- 
otremorine), the non-selective antagonist a ropine, and 
3 selective antagonists (pirenzepine, 4-DAMP and 
methoctramine) which distinguish 3 subclasses of 
muscarinic binding sites in mammalian tissues [17-19]. 
The competition curves are presented in Fig. 4, and the 
calculated apparent dissociation constants hown in 
Table I. All the ligands tested completely inhibited 
[3H]NMS binding, and the data for each could be fitted 
to a single class of sites with a Hill coefficient not 
significantly different from unity (P>0.05). The 
binding sites expressed in yeast membranes from HM1 
therefore appear to constitute a homogeneous popu- 
lation. 
The apparent dissociation constants determined for 
all of the antagonists correlate well with the values 
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Fig. 3. (a) Representative saturation analysis for [aH]NMS binding to 
membranes from yeast pVTUHMI transformants. Shown are total 
binding (©), non-specific binding in the presence of 1/zM atropine 
(a) ,  and specific binding (e), (b) Scatchard representation f the 
specific binding shown in (a). 
reported for muscarinic binding sites in rat as well as 
human cerebral cortical membranes [20,21]. In par- 
ticular, the 3 subtype-selective antagonists inhibited 
[3H]NMS binding with the same rank order of potency 
(4-DAMP I> pirenzepine > > methoctramine)as 
described for mammalian cerebral cortex [21-24], and 
for the HM1 gene product expressed in cultured mam- 
malian cells [6,25]. This finding suggests that the 
recombinant protein detected in binding assays has 
assumed its 'native' conformation i the yeast mem- 
brane. 
The dissociation constants observed for the two 
agonists in the present work are comparable tothe low- 
affinity sites described in brain membranes and in 
transformed mammalian cells expressing cloned HM1. 
In these mammalian systems, an additional high affini- 
ty component is observed which is abolished by incuba- 
tion with GTP and its non-hydrolyzable analogues. The 
high-affinity GTP-sensitive binding of agonists is 
believed to reflect functional interactions with in- 
tracellular G proteins [1]. Based on the present 
findings, it would appear that recombinant HM1 ex- 
pressed in S. cerevisiae does not couple to the en- 
dogenous G protein homologue responsible for signal 
transduction by receptors for mating pheromones. 
Consistent with this conclusion, yeast expressing HM1 
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Fig. 4. Inhibition of specific [3H]NMS binding to yeast membranes 
(from yeast transformed with pVTUHM1). The concentration of 
[3H]NMS was 0.5 nM and specific binding was defined as that 
displaced by 1/zM atropine. Shown are values obtained for atropine 
(-.), 4-DAMP (A), pirenzepine (V), methoctramine (A), oxotre- 
morine (Q), and carbachol (O). 
showed no detectable r sponse to muscarinic agonists in 
a growth inhibition ('halo') assay employed for mating 
pheromon e activity [5] (data not shown). This could 
reflect the inability of the HM1 gene product to 
recognize the yeast G protein, a plausible xplanation 
given the limited sequence similarities between the yeast 
and mammalian homologues [5,26]. It is also possible 
that the heterologous yeast host may fail to transport 
the recombinant receptor to the appropriate subcellular 
compartment, i.e. the plasma membrane. Our inability 
to detect specific [3H]NMS binding to intact cells is con- 
sistent with the latter possibility, though the levels 
measured in crude membranes were near the detection 
limit for the assay procedure with intact cells. 
The number of receptors expressed per cell in yeast in 
this work was considerably ower than those reported 
for a variety of mammalian cell lines stably trans- 
formed with the cloned HM1 gene (ca. 20/cell vs 
10 000-100 000/cell, respectively) [25,27]. On the other 
hand, the specific activity of muscarine binding sites in 
yeast membrane preparations (ca. 20 fmol/mg protein) 
is within 1-2 orders of magnitude of that observed with 
transformed mammalian cells (ca. 200 fmol-2 
pmol/mg protein). The levels obtained in yeast with the 
present system are sufficient to perform detailed 
characterization f antagonist binding properties on 
recombinant receptor, for example in drug screening 
programs, and should prove useful in the analysis of an- 
tagonist binding to site-directed receptor mutants in 
structure-function studies. Given the ease and low cost 
of preparing large quantities of yeast membranes con- 
taining recombinant receptor, this system offers signifi- 
cant advantages over mammalian cell expression for 
such applications. In its present form, however, yeast 
expression of HM1 does not generate sufficient 
amounts of receptor protein to undertake purification 
and structural characterization. Studies are in progress 
to increase receptor levels using different expression 
vectors and yeast strains. 
Previous reports have described the use of microbial 
hosts for the expression of neurotransmitter r ceptors. 
The 4 subunits of the nicotinic acetylcholine r ceptor of 
Torpedo californica, a ligand-gated cation channel, 
have been co-expressed in S. cerevisiae [28]. In that 
study, the four polypeptides represented 0.1-1.0°70 of 
the total membrane protein, but no evidence for 
assembly of functional receptors nor any data on ligand 
binding were presented. Human B-adrenergic receptors, 
members of the G protein-coupled receptor family, 
have been expressed in E. coli from B-galactosidase [29] 
or lamB [30] fusion genes with retention of 'native' 
ligand binding profiles. The results of these studies in- 
dicate that microbial hosts are potentially useful tools 
for receptor studies. A major drawback to the use of 
microorganisms for the expression of mammalian G
protein-coupled receptors, however, is the absence of 
biochemical nd cellular esponses to agonists, due to 
the lack of apropriate intracellular t ansduction com- 
ponents. The previous finding that a mammalian G
protein a subunit (o~-s) can partially compensate for the 
genetic disruption of the yeast alpha homologue [26] 
suggests that functional interactions between mam- 
malian receptors and yeast ransduction machinery may 
be possible. 
In conclusion, we have shown here for the first time 
that a human G protein-coupled receptor can be ex- 
pressed in S. cerevisiae with retention of its characteris- 
tic ligand binding properties. Studies to establish func- 
tional coupling of the recombinant receptor to the 
mating pathway via genetic engineering of the yeast G 
protein subunits are in progress. 
Table 1 
Binding parameters of muscarinic ligands to membranes from yeast transformants 
Atropine 4DAMP Pirenzepine Methoctramine Oxotremorine Charbachol 
Methiodide 
Kapv (2.35+0.19)X10-1° (1.09+0.22) X10 -9 (7-26+0.27) x10-9 (2'30+-0"95) x10-7 (1"19:i:0"12) x10-6 ( 1"71+0"32)×10-4 
NH 0.86 ± 0.05 1.19 ± 0.05 0.92 + 0.04 1.11 _+ 0.10 1.04 + 0.05 0.92 +_ 0.09 
The data were derived from [3H]NMS inhibition experiments shown in Fig. 4 and represent the mean _+ SE (n = 3) for the values of 
apparent affinity (Kapp) and Hill coefficient (nil) for each drug 
24 
Volume 266, number 1,2 FEBS LETTERS June 1990 
Acknowledgements: We thank Dr Daniel Capon for the gift of the 
HM1 gene, Thierry Vernet for pVT102-U and for advice, and Carl 
Juby for synthesizing oligonucleotides. We also thank Drs Dave 
Thomas and Maureen O'Connor-McCourt for critical reading of the 
manuscript. This work was supported in part by a grant from the 
Medical Research Council of Canada (MRC-10050). This is NRC 
publication o. 31162. 
REFERENCES 
[1] Ross, E.M. (1989) Neuron 3, 141-152. 
[2] Lefkowitz, R.J., Kobilka, B.K. and Caron, M.G. (1989) 
Biochem. Pharmacol. 38, 2941-2948. 
[3] Lester, H.A. (1988) Science 241, 1057-1063. 
[4] Herskowitz, I. and Marsh, L. (1987) Cell 50, 995-996. 
[5] Whiteway, M., Hougan, L., Dignard, D., Thomas, D.Y., Bell, 
L., Saari, G.C., Grant, F.J., O'Hara, P. and MacKay, V.L. 
(1989) Cell 56, 467-477. 
[6] Peralta, E.G., Ashkenazi, A., Winslow, J.W., Smith, D.H., 
Ramachandran, J. and Capon, D.J. (1987) EMBO J. 6, 
3923-3929. 
[7] Maniatis, T., Fritsch, E.F., and Sambrook, J. (1982) Cold 
Spring Harbour Laboratory, Cold Spring Harbour, NY. 
[8] Vernet, T., Dignard, D. and Thomas, D.Y. (1987) Gene 52, 
225-233. 
[9] Kunkel, T.A. (1985) Proc. Natl. Acad. Sci. USA 82, 488-492. 
[10] Konopka, J.B., Jenness, D.D. and Hartwell, L.H. (1988) Cell 
54, 609-620. 
[11] Ito, H., Fukuda, Y., Murata, K. and Kimura, A. (1983) J. 
Bacteriol. 153, 163-168. 
[12] Hinnen, A., Hicks, J.B. and Fink, G.R. (1978) Proc. Natl. 
Acad. Sci. USA 75, 1929-1933. 
[13] Chirgwin, J.M., Przybyla, A.E., MacDonald, R.J. and Rutter, 
W.J. (1979) Biochemistry 18, 5294-5299. 
[14] Lowry, O., Rosebrough, N., Farr, A. and Randall, R. (1951) J. 
Biol. Chem. 193, 265-275. 
[15] Blumer, K.J., Reneke, J.E. and Thorner, J. (1988) J. Biol. 
Chem. 263, 10836-10842. 
[16] Martin, C.E. and Scheinbach, S. (1989) Biotechnol. Adv. 7, 
155-185. 
[17] Hammer, R., Berrie, C.P., Birdsall, N.J.M., Burgen, A.S.V. 
and Hulme, E.C. (1980) Nature 283, 90-92. 
[18] Giraldo, E., Hammer, R. and Ladinsky, H. (1987)Life Sciences 
40, 833-840. 
[19] Barlow, R.B. and Shepherd, M.K. (1986) Br. J. Pharmacol. 89, 
837-843. 
[20] Gies, J.-P., Ilien, B. and Landry, Y. (1986) Biochim. Biophys. 
Acta 889, 103-115. 
[21] Giraldo, E., Martos, F., Gomez, A., Garcia, A., Vigano, M.A., 
Ladinsky, H. and Sanchez de La Cuesta, F. (1988) Life Sci. 43, 
1507-1515. 
[22] Nilvebrant, L. and Sparf, B. (1988) Eur. J. Pharmacol. 151, 
83-96. 
[23] Waelbroeck, M., Gillard, M., Rohberecht, P. and Christophe, 
J. (1987) Mol. Pharmacol. 32, 91-99. 
[24] Giraldo, E., Micheletti, R., Montagna, E., Giachetti, A., 
Vigano, M.A., Ladinsky, H. and Melchiorre, C (1988) J. 
Pharmacol. Exp. Ther. 244, 1016-1020. 
[25] Buckley, N.J., Bonnet, T.I., Buckley, C.M. and Brann, M.R. 
0989) Mol. Pharmacol. 35,469-476. 
[26] Dietzel, C. and Kurjan, J. (1987) Cell 50, 1001-1010. 
[27] Peralta, E.G., Ashkenazi, A., Winslow, J.W., Ramachandran, 
J. and Capon, D.J. (1988) Nature 334, 434-437. 
[28] Jansen, K.U., Conroy, W.G., Claudio, T., Fox, T.D., Fujita, 
N., Hamill, O., Lindstrom, J.M., Luther, M. Nelson, N., Ryan, 
K.A., Sweet, M.T. and Hess, G.P. (1989) J. Biol. Chem. 264, 
15022-15027. 
[29] Marullo, S., Delavier-Klutchko, C. Eshdat, Y., Strosberg, A.D. 
and Emorine, L. (1988) Proc. Natl. Acad. Sci. USA 85, 
7551-7555. 
[30] Maruilo, S., Delavier-Klutchko, C., Guillet, J.G., Charbit, A., 
Strosherg, A.D. and Emorine, L.J. (1989) Bio/technology 7,
923-927. 
25 
